LPL Financial
TCRR

LPL Financial’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

LPL Financial’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,485
Closed -$33K – 4608
2022
Q3 		$33K Buy
18,485
+4,350
+31% +$12.6K ﹤0.01% 4282
2022
Q2 		$41K Sell
14,135
-20,150
-59% -$49.7K ﹤0.01% 4265
2022
Q1 		$95K Buy
+34,285
New +$108K ﹤0.01% 3986

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

LPL Financial's TCRR Position: Q4 2022 in Review

LPL Financial sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2022, closing a stake of 18,485 shares — an estimated $33K sold.

LPL Financial first reported a position in TCRR in Q1 2022 and held it in 3 quarters. The position peaked at $95K in Q1 2022. 63 funds tracked by Wall St. Rank hold TCRR as of Q4 2022.

  • LPL Financial reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • LPL Financial sold 18,485 TCR2 Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $33K.
  • LPL Financial first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • LPL Financial's TCR2 Therapeutics Inc. Common Stock position peaked at $95K in Q1 2022.
  • 63 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2022.

Based on LPL Financial's 13F filing for Q4 2022, filed 7 Feb 2023.